Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q3: 2021-11-10 Earnings Summary

EPS of $14.40 beats by $15.07
 | Revenue of $126.73M (8,843.19% Y/Y) beats by $116.81M

Call Start: 8:30 January 1, 0000 9:13 AM ET

Seres Therapeutics, Inc. (NASDAQ:MCRB)
Q3 2021 Earnings Conference Call
November 10, 2021, 8:30 AM ET

Company Participants

Carlo Tanzi – Investor Relations
Eric Shaff – President and Chief Executive Officer
Lisa von Moltke – Chief Medical Officer
David Arkowitz – Chief Financial Officer
Matthew Henn – Chief Scientific Officer
Terri Young – Chief Commercial and Strategy Officer
David Arkowitz – Chief Technology Officer

Conference Call Participants

Joseph Thome – Cowen and Company
Ted Tenthoff – Piper Sandler
Cj – Goldman Sachs
Mark Breidenbach – Oppenheimer
John Newman – Canaccord
Vernon Bernardino – H.C. Wainwright

Operator

Good day and thank you for standing by. Welcome to the Seres Therapeutics Third Quarter Earnings Conference Call. At this time, all participants are in a listen -only mode. After the speakers presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today. Dr. Carlo Tanzi, Investor Relations, please go ahead.

Carlo Tanzi

Thank you and good morning. Our press release with the company's Third Quarter 2021 financial results and a business update became available at 7 AM Eastern Time this morning and can be found on the Investors and News sections of the company's website. I would like to remind you that we will be making forward-looking statements relating to the timing, enrollment, and results of our clinical studies. The anticipated safety profile of our products, regulatory approval, the success of our agreement with the health science, the anticipated market for [Indiscernible] 109, and the promise and potential impact of any of our microbiome therapeutics. Actual results may differ materially.

Additionally, these statements are subject to certain risks and uncertainties which are discussed under

Recommended For You

About MCRB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MCRB